Object Record
Images
Metadata
Object/Catalog Number |
FIC09.11.57 |
Object Name |
Syringe, Hypodermic Glass |
Collection |
Miscellaneous Syringes & Attachment Points |
Object Category |
15: Dental Materials, Tools & Equipment |
Object Sub-category |
Anesthetics |
Description |
"B-D YALE INSULIN" glass hypodermic syringe (1 CC) with steel needle point (needle broken off). Manufactured by Becton Dickinson & Company. |
Material |
Glass, steel |
Length (in) |
2.875 |
Width (in) |
0.5 |
Condition |
Good |
Notes |
DISPLAY Link to Becton Dickinson & Company history: http://www.bd.com/aboutbd/history/ The Beginnning — Windows Media video Maxwell W. Becton and Fairleigh S. Dickinson met on a sales trip in 1897. Months later, they decided to go into business together, sealing their partnership with a handshake. They named their medical device import company Becton, Dickinson and Company. First Sale On October 8, Becton made what is believed to be the company's first sale — a Luer all-glass syringe that sold for $2.50. Luer all-glass syringe 1898 First Patent The First Patent For $40.00, BD acquired a half interest in the patent rights to an all-glass syringe developed by H. Wulfing Luer of Paris, France. 1899 First Logo — Windows Media video The founders chose BD as a trademark for their Company. Over the years the BD name appeared in a wide variety of formats. 100 years later a new logo was adopted as an integral element in the Corporate Identity Program. BD Logo 1904 First Acquisition Acquiring the Philadelphia Surgical Company enabled BD to manufacture its own surgical instruments. This and other early acquisitions expanded the Company's catalog of quality products and brought the talents and manufacturing expertise of new people to BD. 1906 Incorporated The Company incorporated in the State of New Jersey and created a manufacturing facility in East Rutherford, the first in the U.S. built specifically for producing thermometers, hypodermic needles and syringes. 1913 Made in America Made in America — Windows Media video Oscar O. R. Schwidetzky merged his Surgical Supply Import Company with BD, bringing with him the Asepto™ Bulb Syringe and helping to develop the American-made ACE® bandage, a brand name for "All Cotton Elastic." 1921 Modern Stethoscope Andrew W. "Doc" Fleischer, developer of the mercurial sphygmomanometer to measure blood pressure, merged his company with BD and then spent his long career developing and refining the stethoscope and other medical instruments. Andrew W. 1924 First Insulin Syringe BD manufactured its first syringe made specifically for insulin injection. This development marked the beginning of the Company's history in diabetes care. 1925 BD Yale Luer-Lok™ Syringe BD introduced the BD Yale Luer-Lok™ Syringe, designed and patented by Fairleigh S. Dickinson, Sr. It provided a simple, secure method of attaching and removing a needle to and from a syringe. Today, luer lock connectors are the standard for syringes in the U.S. 1934 Innovative Selling Hired to stimulate sagging sales, Edward T.T. Williams revolutionized sales techniques and expanded the Company's customer base. He later served as Chairman of the Board from 1965 to 1967. 1948 New Leadership — Windows Media video Fairleigh S. Dickinson, Jr. and Henry P. Becton, sons of the founders, took over company leadership as President and Vice President, respectively. During their 24-year tenure, BD expanded worldwide, made the successful transition to sterile disposable products and became a public company. 1949 Innovative Selling BD Vacutainer System Joseph Kleiner, hired by BD for his Multifit syringe with interchangeable parts, also brought with him a concept called the Evacutainer — a device to draw blood by vacuum through a needle into a test tube. The product, patented in 1949, evolved to become the BD Vacutainer® Blood Collection System. Wesley J. Howe Wesley J. "Jack" Howe joined BD. He was to play a key role in developing sterility control procedures and refining the process for manufacturing disposable needles and syringes. Howe became Chairman, President and CEO in 1980. Heading West — Windows Media video Columbus, Nebraska became the first BD manufacturing site established outside of New Jersey. 1950 First Sterile Disposable Product First Sterile Disposable Product — Windows Media video BD's first sterile disposable product was a blood collection set developed and sold to the American Red Cross. Efforts to secure a niche in the disposables market continued through the '50s and into the early '60s. BD was the only syringe manufacturer of its day to survive the transition from reusable to disposable medical devices. 1951 Canada BD acquired the Norman S. Wright Company, its Toronto-based Canadian distributor. The formation of BD Canada, Ltd. marked the beginning of BD's international expansion. 1952 Mexico BD acquired MAPAD, S.A. de C.V., based in Mexico City, to produce syringes, needles, and clinical thermometers for the Mexican market. 1953 France BD acquired a plant in Pont-de-Claix from AMI (Applications Mecaniques Industrielles), a company that manufactured reusable hypodermic needles. Two years later, BD acquired a 75% interest in AMI. In 1958, the Company established BD France, S.A. 1954 Salk Polio Trials BD produced the first completely disposable syringe, the BD Hypak™ Syringe, for use in a large-scale field test of the polio vaccine developed by Dr. Jonas Salk. 1955 Baltimore Biological Laboratory (BBL) The acquisition of the Baltimore Biological Laboratory marked BD’s entry into the diagnostic products business. 1956 Brazil BD opened its first manufacturing facility in South America in Juiz de Fora, Brazil. The Company opened a second plant in Curitiba in 1983. BD, which also has offices in São Paulo, is now the largest medical supply company in Brazil. Bard-Parker BD merged with the Bard-Parker Company, known for its history of innovation in the manufacture of surgical blades and knives. Morgan Parker served as Chairman of the BD Board from 1956 to 1964. BD divested the surgical blades business in 2010. 1957 Single-use IV Catheter BD introduced the BD Intracath™ IV Catheter, the first sterile, disposable, through-the-needle IV catheter designed for single use on the market. Puerto Rico BD opened a manufacturing facility in Juncos, Puerto Rico. A plant in Las Piedras was acquired in 1972. Additional facilities came onstream in Cayey in 1982 and in San Lorenzo in 1984. In 2007, BD opened a new facility for BD Biosciences in Cayey. 1959 Disposable Labware The first major milestone in the history of what is now Discovery Labware, a unit of BD Biosciences, was the acquisition of the Falcon Plastics Company, a pioneer in the manufacture of disposable plastic labware. 1959 Broken Bow, Nebraska A new BD facility, the second in Nebraska, opened with 55 employees in a 13,753-sq. ft. building producing 10 types of glass and plastic blood collection tubes, along with other specialty products. After 11 expansions, BD in Broken Bow now employs approximately 400 associates, making it the largest employer in Custer County. The facility produces BD Vacutainer® tubes and urine collection products. 1961 PLASTIPAK Syringe The ‘Disposables Revolution’ After almost ten years of development and testing, BD introduced its first disposable BD Plastipak™ Syringe. In 1962, BD opened a new manufacturing facility in Canaan, Connecticut, dedicated to production of this new syringe. 1962 A Public Company — Windows Media video To raise the capital required for the introduction of sterile disposable products, BD became a publicly held corporation, offering its stock at $25 per share. Sales were $54 million and net income $3 million. Ireland BD opened its first manufacturing facility in Europe in Drogheda, Ireland. A second BD plant was opened in 1969 in Dun Laoghaire. A finance and accounting office was opened in Shannon in 1992. 1963 Fortune 500 BDX BD was listed on the New York Stock Exchange with the symbol: BDX. 1964 New Technologies for Disease Diagnosis BD acquired Clay-Adams., which was to contribute innovative diagnostic products such as the Accu-Stat™ Blood Chemistry Analyzer, precursor of the QBC™ Hematology System. The acquisition also brought two new members to the BD Board of Directors-- Marvin Asnes, who served as President and Chief Operating Officer from 1980 to 1983, and Harry Roth. 1965 Radioimmunodiagnostics With the acquisition of Schwarz BioResearch, BD entered the field of radioimmunodiagnostics. BD held a preeminent position in the radioimmunoassay field until the late ‘80s, when the Company began moving forward with fluorescence-activated and other types of nonradioactive assays. 1966 Holdrege, Nebraska BD opened a manufacturing facility in Holdrege Nebraska. It is now the world’s largest manufacturer of insulin syringes for diabetes. 1969 Europe BD - Europe was established, with headquarters in Grenoble, France. Guided by an ambitious 10-year plan, BD established offices in the Benelux countries (1970); Italy (1971); Germany and Switzerland (1972); Holland and Sweden (1973); followed by manufacturing plants in Germany, Spain (1979 and 1986), the U.K. (1982), Italy and Hungary (2010). In 1982, BD moved its European headquarters to Meylan, France. 1970 FORTUNE 500 For the first time, FORTUNE magazine listed BD as one of the 500 largest American companies. 1971 First Automated Blood Culture System The BD BACTEC™ model 225, (produced by Johnston Labs, which was acquired by BD in 1979) was made commercially available. 1972 Innovative Diagnostic Tools BD acquired Hynson, Westcott & Dunning, a century-old firm that focused on innovative research products and diagnostic tools. 1973 First Fluorescence-Activated Cell Sorter Through licensing arrangements with Stanford University, BD manufactured the first fluorescence-activated cell-sorting system, pioneering the Company's involvement in flow cytometry for cellular analysis. Today, BD is a leader in this field. Research Center BD established the BD Research Center in Research Triangle Park, North Carolina to help the Company meet FDA requirements, research improved manufacturing and process methods and serve as a window to future innovative technologies. 1974 Wesley J. “Jack” Howe was named Chief Executive Officer. In 1980, he became Chairman of the Board, President and CEO. He retired in 1988. 1975 BD Hypak™ Prefilled Syringes A new patent was issued to Claude Imbert, Pharmaceutical Systems - Europe, for a prefilled syringe for injecting heparin, a blood thinner. Today, this product is the worldwide standard for glass prefillable drug delivery systems, combining high-quality design with accurate dosing and easy customization options. 1977 Mountain View, California BD opened a new facility in Mountain View for the manufacture of its innovative fluorescence-activated cell sorter. This location is now the headquarters of the BD Biosciences business segment. 1978 Independence Independence An unfriendly takeover attempt by a large oil company was successfully thwarted when the courts found that the transaction violated the law. BD continued to maintain its independence on behalf of shareholders and employees. 1979 Automated Blood Culture System BD acquired Johnston Laboratories, Inc (JLI), the Baltimore-based company that had developed what is now the BD BACTEC Microbial Detection Systems. JLI’s model 225 BACTEC was the first commercial instrument to automatically detect the growth of microorganisms in blood. Spain BD opened its first manufacturing facility in Spain. In 1986, the Company purchased Fabersanitas Industrial, a syringe manufacturer in Fraga. 1980 First Automated System for Mycobacteria Testing BD introduced the first automated system for mycobacteria testing, the BD BACTEC 460TB System. 1981 United Kingdom A newly constructed facility in Plymouth, U,K. began manufacturing BD Vacutainer® System products to serve growing European markets. An expanded Plymouth facility now manufactures medical devices and diagnostic products that are exported to all regions of the world. England $1 Billion in Sales Sales surpassed the $1 billion milestone. Nine years later, sales exceeded $2 billion. 1982 Sharps Disposal Containers BD was the first injection-device manufacturer to introduce a full line of plastic sharps disposal containers to address the growing concern about healthcare worker safety. Vascular Access Devices To build a leadership position in peripheral vascular access devices on a base of proprietary technology, BD acquired the Deseret Medical Company of Sandy, Utah. 1987 BD in Asia BD in Asia Construction began for a new manufacturing facility for medical products in Singapore. One year later, BD opened a plant in Fukushima, Japan to manufacture diagnostic products. 1988 First Safety-Engineered Syringe BD became the first company to introduce a safety-engineered syringe—the BD Safety-Lok. Beaver Blade Company BD acquired the Beaver Blade Company of Waltham, Massachusetts, a renowned manufacturer of high-quality surgical blades. In 2010, BD divested the Ophthalmic Systems unit which manufactured Beaver blades. 1990 New Manufacturing Facilities BD opened manufacturing facilities in Durham, North Carolina and Sparks, Maryland. 1991 Belgium BD opened a central distribution center in Temse, Belgium to ship medical products throughout Europe, the Middle East and Africa. A second center began shipping diagnostic products in 1994. 1992 BD Vacutainer Safety-LokBlood Collection Set BD introduced the BD Vacutainer® Safety-Lok™ Blood Collection Set, offering needlestick protection following blood-drawing procedures. Raymond V. Gilmartin Raymond V. Gilmartin had joined BD in 1976, bringing his talent for strategic planning. He became Chairman, President and CEO in 1992, departing BD in 1994 to head Merck & Co. New BD Headquarters — Windows Media video BD moved its corporate headquarters from the Company’s original location in East Rutherford, New Jersey to an award-winning facility in Franklin Lakes, New Jersey. 1994 Clateo Castellini Clateo Castellini Clateo Castellini, who joined the Company in 1978 and worked overseas for several years, was named Chairman, President and CEO. BD's revenues that year were $2.6 billion with nearly half coming from operations outside the U.S. 1995 China and India A joint venture was established in China to produce medical products for China and other markets. In India, a subsidiary was formed to manufacture insulin syringes and to market other medical and diagnostic products. China and India 1996 China BD opened a manufacturing facility in Suzhou, China. 1997 Toward Our Second Century — Windows Media video In 1997, BD celebrated its first 100 years — reflecting on past accomplishments and focusing on new opportunities on the horizon. Difco Laboratories BD acquired Difco Laboratories, a manufacturer of media and supplies for industrial microbiology. 1999 New BD logo and identityNew BD Corporate Identity BD implemented a new worldwide identity, building on its 100-year foundation of quality, reliability and commitment to customers and business partners around the world. With a new corporate identity, BD renewed its commitment to Helping all people live healthy lives. PDF View PDF Go to press release Edward J. Ludwig Named President Edward J. Ludwig was named President of BD. In January, 2000 he was also named Chief Executive Officer. Go to press release Edward J. Ludwig Named President BD and UNICEF BD entered into a long-term partnership with UNICEF and the US Fund for UNICEF to help eliminate maternal and neonatal tetanus worldwide. Go to press release Healthcare Worker Safety Healthcare Worker Safety BD launched the BD Safety Compliance Initiative, a nationwide education program to raise awareness about the risk of accidental needlesticks and to help healthcare institutions comply with federal mandates for safety-engineered devices. BD Safety Compliance Initiative 2001 Gentest Corporation BD acquired Gentest Corporation, a leader in drug metabolism and toxicology testing of drugs under development. 2002 Ludwig Named Board Chairman Edward J. Ludwig was named Chairman of the Board of Directors. Go to press release $1 Million for AIDS Vaccine BD pledged $1 million to the International AIDS Vaccine Initiative (IAVI). This public-private partnership helps ensure that promising candidates for a vaccine to prevent AIDS advance rapidly through human testing and that developing countries have the supplies and training needed to conduct their own vaccine trials. BD One of 'America's Most Admired Companies' FORTUNE magazine recognized BD as one of "America's Most Admired Companies" for the first time. BD strengthened its position to third overall in the medical products and equipment industry and received the industry's top ranking for quality of products and services. 2003 Trusted Partners Campaign BD embarked upon a global communications campaign highlighting its 100-year history of Helping all people live healthy lives. PDF View Campaign Ad BD FACSAria™ Cell Sorter BD Biosciences launched the BD FACSAria™ Cell Sorter, the first entirely new instrument in the next-generation portfolio of flow cytometers. BD Accuspray™ Nasal Spray System The BD Accuspray™ Nasal Drug Delivery System for administering FluMist® influenza virus vaccine became the first FDA-approved nasal spray flu vaccine. Affordable CD4 Testing for HIV/AIDS BD entered into an agreement with The William J. Clinton Presidential Foundation to provide affordable CD4 testing for HIV/AIDS to many countries in the developing world. Atto Bioscience BD acquired Atto Bioscience, a Maryland-based manufacturer of optical instrumentation, software and reagents for real-time analysis of interactions taking place in living cells. Go to press release 2005 Great Place to Work BD first appeared on the list of “Best Places to Work in New Jersey,’ assembled by NJBIZ magazine. Dow Jones Sustainability Index BD was first selected as a component of the Dow Jones Sustainability Index North America; it has been included on the list ever since. Since 2007, the Company has also been included in the Dow Jones Sustainability World Index. BD Volunteer Service Program BD associates traveled to Africa in the first of a series of BD-sponsored efforts that combine contributions of cash and product with volunteer work to improve healthcare in remote locations. BD Volunteer Service Program Trip Group line BD Acquires GeneOhm Sciences Rapid Detection of Bacterial Organisms The acquisition of GeneOhm, a pioneer in the development of molecular diagnostic testing for the rapid detection of bacterial organisms, positioned BD to become a leader in the prevention of the global healthcare problem of healthcare-associated infections (HAIs). Go to press release line Advanced Cancer Diagnostics The acquisition of TriPath Imaging expanded BD's presence in cancer diagnostics and represented a key element in the strategy to drive growth through innovation. Go to press release 2007 BD Among Most Ethical Companies Ethisphere magazine included BD in its inaugural listing of the World’s Most Ethical Companies; BD has remained on this annual list since then. Plasma Polymerization Technology BD acquired Plasso Technology, Ltd. and its plasma polymerization technology, which enables the development of next-generation surfaces for application in life science research. 2008 Advanced Flow-Cytometry Technologies BD acquired Cytopeia, a developer of advanced flow-cytometry cell-sorting instruments. Go to press release New Manufacturing Center in Quebec BD opened the new BD Diagnostics – GeneOhm manufacturing facility in Quebec. It will also serve as a center of research and development for BD’s rapid molecular diagnostic products. Go to press release 2009 Forlenza Becomes BD President Vincent A. Forlenza, who joined BD in 1980, assumed the position of BD President. In July 2010, he was also named Chief Operating Officer, with Edward J. Ludwig continuing to serve as Chief Executive Officer and Chairman of the Board. Go to press release Vincent A. Forlenza Joint Initiative With PEPFAR BD launched a public-private partnership with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to help improve blood-drawing practices in sub-Saharan Africa. Go to press release Home Healthcare Product Line Divested BD sold the assets associated with the Home Healthcare product line to 3M, including product inventory, brand names and manufacturing associated with ACE®, Tensor®, Bauer & Black® and Tru-Fit® products, and thermometers. 2010 Hungary BD opened its first production facility in Tatabánya, Hungary. The BD Medical - Pharmaceutical Systems facility will manufacture prefillable syringes to be sold to pharmaceutical and biotechnology firms for use with their injectable drugs. HandyLab BD acquired HandyLab, Inc., a developer and manufacturer of molecular diagnostic assays and automation platforms. New Facility in Mexico BD celebrated the opening of a new production facility in San Luis Potosi, Mexico. The Company first established operations in Mexico in 1957. Its other facilities are in Cuautitlán Izcalli, in the State of México; Nogales, Sonora; and Mexico City. Ophthalmic Systems Unit Divested BD divested certain assets of its BD Medical segment, including the Ophthalmic Systems unit and the surgical blades, critical care and extended-dwell catheter product platforms of the Medical Surgical Systems unit. Bioscience Production Facility in Miami A new BD Biosciences - Advanced Bioprocessing AF2™ Production Facility in Miami, Florida is the industry’s first fully dedicated, stand-alone "antibiotic-free" and "animal-free" facility for producing high-quality cell culture media and supplements used in the production of vaccines and biopharmaceuticals. Windows Media is a registered trademark of Microsoft Corporation FluMist® is a registered trademark Medimmune Vaccines, Inc. BD 1 Becton Drive Franklin Lakes, NJ USA 07417 201.847.6800 www.bd.com Unless otherwise noted, BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. © 2011 BD |
Number of images |
1.0 |
Catalog date |
2011-08-18 |
Dimensions |
W-0.5 L-2.875 inches |
Caption |
Hypodermic Glass Syringe |
Made |
United States: Becton Dickinson & Company, Philadelphia, PA |